Anja Bösch
Resistance development in to delafloxacin at pHs 6.0 and 7.3 compared to ciprofloxacin.
Bösch A, Macha M, Qun R, Kohler P, Qi W, Babouee Flury B. Resistance development in to delafloxacin at pHs 6.0 and 7.3 compared to ciprofloxacin. Antimicrob Agents Chemother 2023; 67:e0162522.
26.10.2023Resistance development in to delafloxacin at pHs 6.0 and 7.3 compared to ciprofloxacin.
26.10.2023Antimicrob Agents Chemother 2023; 67:e0162522
Bösch Anja, Macha Magreth, Qun Ren, Kohler Philipp, Qi Weihong, Babouee Flury Baharak
Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical isolates from Switzerland.
Babouee Flury B, Bösch A, Gisler V, Egli A, Seiffert S, Nolte O, Findlay J. Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical isolates from Switzerland. Front Cell Infect Microbiol 2023; 13:1098944.
25.04.2023Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical isolates from Switzerland.
25.04.2023Front Cell Infect Microbiol 2023; 13:1098944
Babouee Flury Baharak, Bösch Anja, Gisler Valentin, Egli Adrian, Seiffert Salome N, Nolte Oliver, Findlay Jacqueline
AmpC hyperproduction in a Cedecea davisae implant-associated bone infection during treatment: a case report and therapeutic implications.
Notter J, Seiffert S, Zimmermann-Kogadeeva M, Bösch A, Wenger R, Strahm C, Frischknecht M, Livermore D, Babouee Flury B. AmpC hyperproduction in a Cedecea davisae implant-associated bone infection during treatment: a case report and therapeutic implications. BMC Infect Dis 2022; 22:33.
06.01.2022AmpC hyperproduction in a Cedecea davisae implant-associated bone infection during treatment: a case report and therapeutic implications.
06.01.2022BMC Infect Dis 2022; 22:33
Notter Julia, Seiffert Salome N, Zimmermann-Kogadeeva Maria, Bösch Anja, Wenger Robert, Strahm Carol, Frischknecht Manuel, Livermore David M, Babouee Flury Baharak